Newsletter Subscription

Enter Name and Email

14 March 2011 - Just published: Review of antipsychotics pharmacology

Several recent antipsychotics combine antagonism (or partial agonism) at D2 receptors with agonism at serotonin 5-HT1A receptors. Such drugs include aripiprazole (Abilify®, BMS/Otsuka), Lurasidone (Latuda®, DainipponSumitomo) and  cariprazine (PhIII, Forest/Richter). Other compounds that have been extensively characterised at a pharmacological level, including adoprazine, SSR181507 and F15063.

Combined D2/5-HT1A properties are associated with improved cognition, reduced mood deficits and lessened extrapyramidal symptoms (EPS) liability. However, marked differences are observed in the pharmacological profiles of the above drugs suggesting that modest differences in their receptor interactions translate to substantial divergence in their therapeutic potential.

This new review discusses these issues on the basis of systematic pharmacological comparisons and the latest available publications. For more information, Contact.

 

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Newman-Tancredi A, Kleven MS.

Psychopharmacology (Berl). 2011 Mar 11. [Epub ahead of print]